{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:08:39Z","timestamp":1792058919807,"version":"4.4.0"},"reference-count":122,"publisher":"Tech Science Press","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.067666","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T08:48:31Z","timestamp":1756111711000},"page":"2673-2697","source":"Crossref","is-referenced-by-count":4,"title":["Multi-Target Biological Activities of Podophyllotoxin-Derived Natural Products"],"prefix":"10.32604","volume":"33","author":[{"given":"Yuhan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaden A. M.","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham R.","family":"El-Seedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Coghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","first-page":"285","article-title":"Podophyllotoxin: a novel potential natural anticancer agent","volume":"7","author":"Ardalani","year":"2017","journal-title":"Avicenna J Phytomed"},{"key":"ref2","first-page":"44","article-title":"On the active constituents of podophyllin","volume":"102","author":"Podwissotzki","year":"1882","journal-title":"Am J Pharm"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.3390\/ijms22126602","article-title":"Natural polyphenols as modulators of etoposide anti-cancer activity","volume":"22","author":"Kluska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"6654","DOI":"10.1093\/nar\/gkaa483","article-title":"Topoisomerase II contributes to DNA secondary structure-mediated double-stranded breaks","volume":"48","author":"Szlachta","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"16774","DOI":"10.1021\/acs.jmedchem.2c01595","article-title":"Discovery of novel N-heterocyclic-fused deoxypodophyllotoxin analogues as tubulin polymerization inhibitors targeting the colchicine-binding site for cancer treatment","volume":"65","author":"Leng","year":"2022","journal-title":"J Med Chem"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature02393","article-title":"Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain","volume":"428","author":"Ravelli","year":"2004","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.4014\/jmb.2207.07012","article-title":"Deoxypodophyllotoxin induces ROS-mediated apoptosis by modulating the PI3K\/AKT and p38 MAPK-dependent signaling in oral squamous cell carcinoma","volume":"32","author":"Seo","year":"2022","journal-title":"J Microbiol Biotechnol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4062\/biomolther.2021.143","article-title":"Podophyllotoxin induces ROS-mediated apoptosis and cell cycle arrest in human colorectal cancer cells via p38 MAPK signaling","volume":"29","author":"Lee","year":"2021","journal-title":"Biomol Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s12885-024-12244-3","article-title":"PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis","volume":"24","author":"Shi","year":"2024","journal-title":"BMC Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1158\/2326-6066.CIR-22-0483","article-title":"Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity","volume":"11","author":"Han","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/13880209.2024.2318350","article-title":"Design, synthesis and biological evaluation of novel podophyllotoxin derivatives as tubulin-targeting anticancer agents","volume":"62","author":"Guo","year":"2024","journal-title":"Pharm Biol"},{"key":"ref12","first-page":"229","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"114643","DOI":"10.1016\/j.biopha.2023.114643","article-title":"Overcoming cancer multi-drug resistance (MDR): reasons, mechanisms, nanotherapeutic solutions, and challenges","volume":"162","author":"Duan","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"ref14","first-page":"70\u20138388","article-title":"Anticancer structure activity relationship of podophyllotoxin of various species of Podophyllum","volume":"13","author":"Nishad","year":"2024","journal-title":"Ann Phytomed Int J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2174\/1570180820666230606161639","article-title":"Design of podophyllotoxin-based hybrid compounds as potential anticancer agents","volume":"21","author":"Zhang","year":"2024","journal-title":"Lett Drug Des Discov"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"112830","DOI":"10.1016\/j.ejmech.2020.112830","article-title":"Recent advances of podophyllotoxin\/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: an update (2010\u20132020)","volume":"208","author":"Xiao","year":"2020","journal-title":"Eur J Med Chem"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.21319","article-title":"Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents","volume":"35","author":"Liu","year":"2015","journal-title":"Med Res Rev"},{"key":"ref18","first-page":"1","article-title":"C-4 analogues of podophyllotoxin as tubulin inhibitors: synthesis, biological evaluation, and structure-activity relationship","volume":"19","author":"Lu","year":"2024","journal-title":"Nat Prod Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ejmech.2003.05.001","article-title":"Synthesis, cytotoxicity and antiviral activity of podophyllotoxin analogues modified in the E-ring","volume":"38","author":"Castro","year":"2003","journal-title":"Eur J Med Chem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3389\/fchem.2019.00253","article-title":"Synthesis and biological evaluation of 4\u03b2-N-acetylamino substituted podophyllotoxin derivatives as novel anticancer agents","volume":"7","author":"Wei","year":"2019","journal-title":"Front Chem"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1039\/D2NP00028H","article-title":"Biosynthesis, total synthesis, and pharmacological activities of aryltetralin-type lignan podophyllotoxin and its derivatives","volume":"39","author":"Shen","year":"2022","journal-title":"Nat Prod Rep"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/plants13223233","volume":"13","author":"Joji\u0107","year":"2024","journal-title":"Plants"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"175089","DOI":"10.1016\/j.ejphar.2022.175089","article-title":"A comprehensive insight into the antineoplastic activities and molecular mechanisms of deoxypodophyllotoxin: recent trends, challenges, and future outlook","volume":"928","author":"Mottaghi","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semcancer.2022.07.007","article-title":"Necroptosis pathways in tumorigenesis","volume":"86","author":"Zhang","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"ref25","first-page":"561","article-title":"Research progress in necroptosis","volume":"47","author":"Shi","year":"2020","journal-title":"Prog Biochem Biophys"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15698\/cst2020.01.208","article-title":"Necroptosis, tumor necrosis and tumorigenesis","volume":"4","author":"Liu","year":"2019","journal-title":"Cell Stress"},{"key":"ref27","first-page":"351","article-title":"Parthanatos and apoptosis: unraveling their roles in cancer cell death and therapy resistance","volume":"24","author":"Gupta","year":"2025","journal-title":"EXCLI J"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.canlet.2015.11.044","article-title":"Deoxypodophyllotoxin triggers parthanatos in glioma cells via induction of excessive ROS","volume":"371","author":"Ma","year":"2016","journal-title":"Cancer Lett"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/s41401-023-01091-w","article-title":"TAX1BP1 contributes to deoxypodophyllotoxin-induced glioma cell parthanatos via inducing nuclear translocation of AIF by activation of mitochondrial respiratory chain complex I","volume":"44","author":"Wang","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.ejmech.2011.02.016","article-title":"4\u03b2-[(4-Alkyl)-1, 2, 3-triazol-1-yl] podophyllotoxins as anticancer compounds: design, synthesis and biological evaluation","volume":"46","author":"Reddy","year":"2011","journal-title":"Eur J Med Chem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s13659-015-0057-3","article-title":"Synthesis and anticancer activity of 4\u03b2-triazole-podophyllotoxin glycosides","volume":"5","author":"Zi","year":"2015","journal-title":"Nat Prod Bioprospect"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/cbdd.13436","article-title":"Click chemistry-based synthesis and cytotoxic activity evaluation of 4\u03b1-triazole acetate podophyllotoxin derivatives","volume":"93","author":"Hou","year":"2019","journal-title":"Chem Biol Drug Des"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"14924","DOI":"10.1002\/slct.202003810","volume":"5","author":"Bkhaitan","year":"2020","journal-title":"ChemistrySelect"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.bmcl.2019.06.060","article-title":"Design and synthesis of 4\u03b2-Acetamidobenzofuranone-podophyllotoxin hybrids and their anti-cancer evaluation","volume":"29","author":"Paidakula","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bmcl.2017.12.012","volume":"28","author":"Sang","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejmech.2014.10.050","article-title":"Investigation of podophyllotoxin esters as potential anticancer agents: synthesis, biological studies and tubulin inhibition properties","volume":"89","author":"Shareef","year":"2015","journal-title":"Eur J Med Chem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bmcl.2015.11.042","article-title":"Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent","volume":"26","author":"Zhang","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1016\/j.ejmech.2011.06.004","article-title":"Synthesis and biological evaluation of derivatives of 4-deoxypodophyllotoxin as antitumor agents","volume":"46","author":"Jin","year":"2011","journal-title":"Eur J Med Chem"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.bmc.2017.11.026","article-title":"Podophyllotoxin derivatives as an excellent anticancer aspirant for future chemotherapy: a key current imminent needs","volume":"26","author":"Zhang","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.2174\/1568026621666210113163327","article-title":"Recent advances in the application of podophyllotoxin derivatives to fight against multidrug-resistant cancer cells","volume":"21","author":"Guo","year":"2021","journal-title":"Curr Top Med Chem"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/1871520614666141130125623","article-title":"Recent developments towards podophyllotoxin congeners as potential apoptosis inducers","volume":"15","author":"Kamal","year":"2015","journal-title":"Anticancer Agents Med Chem"},{"key":"ref42","unstructured":"Study of etoposide monotherapy in treating patients with recurrent or metastatic breast cancer [Internet]. [cited 2025 Jul 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01492556."},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1186\/s12885-024-13041-8","article-title":"Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Cancer"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/sj.bjc.6603810","article-title":"Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702","volume":"97","author":"Okamoto","year":"2007","journal-title":"Br J Cancer"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12890-024-03459-y","article-title":"Carboplatin in combination with etoposide for advanced small cell lung cancer complicated with idiopathic interstitial pneumonia: a single-arm phase II study","volume":"25","author":"Matsumoto","year":"2025","journal-title":"BMC Pulm Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.18.00264","article-title":"Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN, 2511 study","volume":"37","author":"Owonikoko","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-024-02115-5","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e087302","DOI":"10.1136\/bmjopen-2024-087302","article-title":"Neoadjuvant adebrelimab combined with chemotherapy (cisplatin\/carboplatin and etoposide) for limited-stage small-cell lung cancer: a study protocol of phase 2 trial (NIUS)","volume":"15","author":"Liu","year":"2025","journal-title":"BMJ Open"},{"key":"ref49","unstructured":"Durvalumab \u00b1 tremelimumab in combination with platinum based chemotherapy in untreated extensive-stage small cell lung cancer (CASPIAN) (CASPIAN) [Internet]. [cited 2025 Jul 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03043872."},{"key":"ref50","unstructured":"A study evaluating the safety of abt-263 in combination with etoposide\/cisplatin in subjects with cancer [Internet]. [cited 2025 Jul 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00878449."},{"key":"ref51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0169-5002(99)00120-8","article-title":"Economic evaluation in a randomized phase III clinical trial comparing gemcitabine\/cisplatin and etoposide\/cisplatin in non-small cell lung cancer","volume":"28","author":"Sacrist\u00e1n","year":"2000","journal-title":"Lung Cancer"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1080\/10428194.2024.2361111","article-title":"A phase ib clinical trial of oral ciprofloxacin and etoposide in subjects with resistant acute myeloid leukemia","volume":"65","author":"Gera","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"ref53","unstructured":"Intensified conditioning regimen with high-dose-etoposide for allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia [Internet]. [cited 2025 Jul 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01457040."},{"key":"ref54","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0090-8258(87)90257-5","article-title":"Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma","volume":"27","author":"Dottino","year":"1987","journal-title":"Gynecol Oncol"},{"key":"ref55","unstructured":"Etoposide\/cisplatin compared with irinotecan\/cisplatin for advanced gastrointestinal neuroendocrine tumor G3 type [Internet]. [cited 2025 Jul 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03963193."},{"key":"ref56","unstructured":"Valproate and etoposide for patients with neuronal tumors and brain metastases [Internet]. [cited 2025 Jul 1]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00513162."},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jamaoncol.2024.4381","article-title":"Lenvatinib plus ifosfamide and etoposide in children and young adults with relapsed osteosarcoma: a phase 2 randomized clinical trial","volume":"10","author":"Gaspar","year":"2024","journal-title":"JAMA Oncol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"106535","DOI":"10.1016\/j.intimp.2020.106535","article-title":"Breast cancer: biology, biomarkers, and treatments","volume":"84","author":"Barzaman","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"104351","DOI":"10.1016\/j.critrevonc.2024.104351","article-title":"Recent strategies to overcome breast cancer resistance","volume":"197","author":"Khan","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/cac2.12291","article-title":"Cancer-associated fibroblasts in breast cancer: challenges and opportunities","volume":"42","author":"Hu","year":"2022","journal-title":"Cancer Commun"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3389\/fphar.2020.01211","article-title":"Target analysis and mechanism of podophyllotoxin in the treatment of triple-negative breast cancer","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1016\/j.bmc.2019.07.005","article-title":"Aisa HA. 1, 2, 3-Triazole-containing hybrids as leads in medicinal chemistry: a recent overview","volume":"27","author":"Bozorov","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.ejmech.2011.07.024","article-title":"Synthesis of 4\u03b2-triazole-podophyllotoxin derivatives by azide-alkyne cycloaddition and biological evaluation as potential antitumor agents","volume":"46","author":"Chen","year":"2011","journal-title":"Eur J Med Chem"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"13992","DOI":"10.3390\/molecules181113992","article-title":"Synthesis and anticancer activity of glucosylated podophyllotoxin derivatives linked via 4\u03b2-triazole rings","volume":"18","author":"Zi","year":"2013","journal-title":"Molecules"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.2174\/0929867325666180403145137","article-title":"Glycosides from medicinal plants as potential anticancer agents: emerging trends towards future drugs","volume":"26","author":"Khan","year":"2019","journal-title":"Curr Med Chem"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2174\/1871530319666181128104831","article-title":"Plant-derived glycosides with \u03b1-glucosidase inhibitory activity: current standing and future prospects","volume":"19","author":"Khan","year":"2019","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref67","first-page":"1934578X19860668","article-title":"Synthesis and cytotoxicities of novel podophyllotoxin xyloside derivatives","volume":"14","author":"Zi","year":"2019","journal-title":"Nat Prod Commun"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.2147\/DDDT.S215895","article-title":"Glucoside derivatives of podophyllotoxin: synthesis, physicochemical properties, and cytotoxicity","volume":"13","author":"Zi","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejmech.2018.05.052","article-title":"Synthesis and biological evaluation of podophyllotoxin derivatives as selective antitumor agents","volume":"155","author":"Wu","year":"2018","journal-title":"Eur J Med Chem"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1016\/j.bmc.2013.08.051","article-title":"Quinazolino linked 4\u03b2-amidopodophyllotoxin conjugates regulate angiogenic pathway and control breast cancer cell proliferation","volume":"21","author":"Kamal","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/1871520614666140608150448","volume":"15","author":"Benzina","year":"2015","journal-title":"Anticancer Agents Med Chem"},{"key":"ref72","first-page":"1330","article-title":"Lung cancer statistics","volume":"130","author":"Kratzer","year":"2024","journal-title":"2023 Cancer"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41589-022-01235-9","article-title":"Etoposide promotes DNA loop trapping and barrier formation by topoisomerase II","volume":"19","author":"Le","year":"2023","journal-title":"Nat Chem Biol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/13880200500220854","volume":"43","author":"Javidnia","year":"2005","journal-title":"Pharm Biol"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"153355","DOI":"10.1016\/j.phymed.2020.153355","article-title":"Targeted inhibition of c-MET by podophyllotoxin promotes caspase-dependent apoptosis and suppresses cell growth in gefitinib-resistant non-small cell lung cancer cells","volume":"80","author":"Oh","year":"2021","journal-title":"Phytomedicine"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3892\/ijo.2015.3123","article-title":"Podophyllotoxin acetate triggers anticancer effects against non-small cell lung cancer cells by promoting cell death via cell cycle arrest, ER stress and autophagy","volume":"47","author":"Choi","year":"2015","journal-title":"Int J Oncol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1021\/np060430o","volume":"70","author":"Jiang","year":"2007","journal-title":"J Nat Prod"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"128174","DOI":"10.1016\/j.bmcl.2021.128174","article-title":"The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K\/Akt signaling pathway","volume":"46","author":"Zhao","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejmech.2014.02.030","article-title":"A convergent synthesis of alkyne-azide cycloaddition derivatives of 4-\u03b1,\u03b2-2-propyne podophyllotoxin depicting potent cytotoxic activity","volume":"77","author":"Zilla","year":"2014","journal-title":"Eur J Med Chem"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1016\/j.bmcl.2015.07.100","volume":"25","author":"Shankaraiah","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ejmech.2017.12.050","article-title":"4\u03b2-amidotriazole linked podophyllotoxin congeners: dNA topoisomerase-II\u03b1 inhibition and potential anticancer agents for prostate cancer","volume":"144","author":"Reddy","year":"2018","journal-title":"Eur J Med Chem"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3892\/ol.2016.4943","article-title":"Anticancer effect of deoxypodophyllotoxin induces apoptosis of human prostate cancer cells","volume":"12","author":"Hu","year":"2016","journal-title":"Oncol Lett"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/molecules22040628","article-title":"Synthesis and antiproliferative activity of novel all-trans-retinoic acid-podophyllotoxin conjugate towards human gastric cancer cells","volume":"22","author":"Zhang","year":"2017","journal-title":"Molecules"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/biom11040603","article-title":"Podophyllotoxin: history, recent advances and future prospects","volume":"11","author":"Shah","year":"2021","journal-title":"Biomolecules"},{"key":"ref85","first-page":"87","article-title":"Podophyllotoxin and their glycosidic derivatives","volume":"2","author":"Nagar","year":"2011","journal-title":"Pharmacophore"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"709075","DOI":"10.3389\/fcell.2021.709075","article-title":"Insight into the molecular mechanism of podophyllotoxin derivatives as anticancer drugs","volume":"9","author":"Fan","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"1191498","DOI":"10.3389\/fchem.2023.1191498","article-title":"Synthesis and anticancer activity of podophyllotoxin derivatives with nitrogen-containing heterocycles","volume":"11","author":"Yin","year":"2023","journal-title":"Front Chem"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3892\/ijmm.2015.2068","volume":"35","author":"Cao","year":"2015","journal-title":"Int J Mol Med"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1039\/C9TX00103D","article-title":"Dendrimer-conjugated podophyllotoxin suppresses DENA-induced HCC progression by modulation of inflammatory and fibrogenic factors","volume":"8","author":"Sharma","year":"2019","journal-title":"Toxicol Res"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/1878-0261.12743","article-title":"An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer","volume":"14","author":"Pan","year":"2020","journal-title":"Mol Oncol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2174\/1381612003398582","article-title":"Antitumor properties of podophyllotoxin and related compounds","volume":"6","author":"Gordaliza","year":"2000","journal-title":"Curr Pharm Des"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/cbdd.13605","volume":"94","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2019","journal-title":"Chem Biol Drug Des"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/ijms26030958","article-title":"The effects of podophyllotoxin derivatives on noncancerous diseases: a systematic review","volume":"26","author":"Strus","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/molecules25010183","article-title":"Lignans and their derivatives from plants as antivirals","volume":"25","author":"Cui","year":"2020","journal-title":"Molecules"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"267","DOI":"10.59467\/IJHC.2024.34.267","article-title":"Synthesis and biological activity of some new podophyllotoxin bearing pyrimidine moiety","volume":"34","author":"Sowmya","year":"2024","journal-title":"Indian J Heterocycl Chem"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00044-014-1100-3","article-title":"Synthesis and biological screening of pyrazole moiety containing analogs of podophyllotoxin","volume":"24","author":"Umesha","year":"2015","journal-title":"Med Chem Res"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.3390\/molecules23123303","volume":"23","author":"Rocha","year":"2018","journal-title":"Molecules"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/jebm.12494","article-title":"Clinical guideline for the diagnosis and treatment of cutaneous warts","volume":"15","author":"Zhu","year":"2022","journal-title":"J Evid Based Med"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4103\/ijdvl.IJDVL_148_19","article-title":"A short, 8-week course of imiquimod 5% cream versus podophyllotoxin in the treatment of anogenital warts: a retrospective comparative cohort study","volume":"87","author":"Nicolaidou","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24470","article-title":"Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT","volume":"24","author":"Gilson","year":"2020","journal-title":"Health Technol Assess"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41589-021-00791-w","article-title":"A molecular trap inside microtubules probes luminal access by soluble proteins","volume":"17","author":"Nihongaki","year":"2021","journal-title":"Nat Chem Biol"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3390\/cells9112356","article-title":"The tubulin code in mitosis and cancer","volume":"9","author":"Lopes","year":"2020","journal-title":"Cells"},{"key":"ref103","first-page":"1913","article-title":"CDK inhibitors in cancer therapy, an overview of recent development","volume":"11","author":"Zhang","year":"2021","journal-title":"Am J Cancer Res"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/cells10051182","article-title":"Transcriptional CDK inhibitors CYC065 and THZ1 induce apoptosis in glioma stem cells derived from recurrent GBM","volume":"10","author":"Juric","year":"2021","journal-title":"Cells"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"pe5","DOI":"10.1091\/mbc.E22-06-0196","article-title":"CDK signaling via nonconventional CDK phosphorylation sites","volume":"34","author":"Valk","year":"2023","journal-title":"Mol Biol Cell"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.semcdb.2020.04.003","article-title":"Less-well known functions of cyclin\/CDK complexes","volume":"107","author":"Palmer","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3109\/10799893.2015.1030412","article-title":"Signaling pathway of MAPK\/ERK in cell proliferation, differentiation, migration, senescence and apoptosis","volume":"35","author":"Sun","year":"2015","journal-title":"J Recept Signal Transduct Res"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2174\/1568009621666211103113339","article-title":"The therapeutic potential of MAPK\/ERK inhibitors in the treatment of colorectal cancer","volume":"21","author":"Pashirzad","year":"2021","journal-title":"Curr Cancer Drug Targets"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.3390\/cancers13123026","article-title":"MAPK\/ERK signaling pathway in hepatocellular carcinoma","volume":"13","author":"Moon","year":"2021","journal-title":"Cancers"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.3390\/ijms25063178","article-title":"PI3K\/Akt\/mTOR signaling pathway as a target for colorectal cancer treatment","volume":"25","author":"Leiphrakpam","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","article-title":"Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance","volume":"59","author":"Ediriweera","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"E9181","DOI":"10.3390\/ijms21239181","article-title":"NF-\u03baB and disease","volume":"21","author":"Poma","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: p53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"2365408","DOI":"10.1080\/0886022X.2024.2365408","article-title":"Hyperactivation of p53 contributes to mitotic catastrophe in podocytes through regulation of the Wee1\/CDK1\/cyclin B1 axis","volume":"46","author":"Feng","year":"2024","journal-title":"Ren Fail"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2018.11.019","article-title":"Cyclin B1\/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance","volume":"443","author":"Xie","year":"2019","journal-title":"Cancer Lett"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1002\/1873-3468.13591","article-title":"Orchestration of the spindle assembly checkpoint by CDK1-cyclin B1","volume":"593","author":"Hayward","year":"2019","journal-title":"FEBS Lett"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41556-022-00886-z","article-title":"CDK1-cyclin-B1-induced kindlin degradation drives focal adhesion disassembly at mitotic entry","volume":"24","author":"Chen","year":"2022","journal-title":"Nat Cell Biol"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1126\/science.1072682","article-title":"Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases","volume":"298","author":"Johnson","year":"2002","journal-title":"Science"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.advenzreg.2006.01.004","article-title":"Roles of the RAF\/MEK\/ERK and PI3K\/PTEN\/AKT pathways in malignant transformation and drug resistance","volume":"46","author":"McCubrey","year":"2006","journal-title":"Adv Enzyme Regul"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial intelligence in drug development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat Med"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"107772","DOI":"10.1016\/j.bioorg.2024.107772","article-title":"Development of natural product-based targeted protein degraders as anticancer agents","volume":"153","author":"Chen","year":"2024","journal-title":"Bioorg Chem"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-10\/OncolRes-33-10-67666\/OncolRes-33-67666.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:22:09Z","timestamp":1763346129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n10\/63894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":122,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.067666","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}